In 2016
Introduction
This chapter analyses the routine biochemistry data of patients on established haemodialysis (HD) and peritoneal dialysis (PD) from all renal centres in the UK in 2016. The UK Renal Registry (UKRR) collects data from all renal centres in England, Wales and Northern Ireland and receives Scottish data via the Scottish Renal Registry. The attainment of biochemistry parameters is compared at a renal centre and national level as well as against national performance measures as set out in the Renal Association (RA) guidelines.
The audit measures listed in table 8.1 applied in 2016 and are obtained from several different RA guidelines [1] which are updated over time:
. CKD-mineral bone disease 2015 guideline [2] . Haemodialysis 2009 guideline [3] -update due in 2018 . Peritoneal dialysis 2010 guideline [4] . Cardiovascular disease 2010 guideline [5] No new guidelines were published during the 2016 calendar year and therefore the same audit standards apply as were used for the 2015 analyses. In 2017, updated KDIGO international chronic kidney disease -mineral bone disorder (CKD-MBD) guidelines were published which have not advocated changes in target biochemical parameters in relation to dialysis patients citing the ongoing lack of strong evidence [6] . They highlight the importance in identifying trends in parameters rather than reacting to isolated measurements and to understand the complex interplay of the variables involved. They advise that clinicians individualise treatment and suggest that changes aimed at improving biochemical parameters could have inadvertent detrimental effects which are more difficult to measure such as in relation to bone mineral density or arterial calcification. In this context, out of range observations (e.g. hyperphosphataemia or PTH below target range) need to be interpreted cautiously as they may relate to different clinical problems or population characteristics.
The most recent RA renal bone disease guidelines offer two audit measures, firstly the proportion of patients with Summary measures at centre and country level are presented in various formats but not as cumulative frequency curves.
Cumulative frequency curves of pre-dialysis serum calcium (adjusted for albumin) and phosphate concentrations Partly Summary measures at centre and country level are presented in various formats but not as cumulative frequency curves serum phosphate ,1.7 mmol/L and secondly the proportion of patients with all bone parameters within target range [2] . The target range for phosphate recommended in the guideline is 1.1-1.7 mmol/L (not ,1.7 mmol/L as for the phosphate audit measure). Therefore the authors have interpreted the latter audit measure to include this recommended target range for phosphate of 1.1-1.7 mmol/L which results in different measures of phosphate being used at different points in the chapter and readers should be aware of this when interpreting these results.
For the first time, a sufficient number of centres have returned data in relation to pre-dialysis potassium. The most recent RA haemodialysis guideline recommends an audit measure of cumulative frequency curves of pre-dialysis potassium and includes a target range for pre-dialysis potassium of 4.0-6.0 mmol/L [3] . There is no recommendation on serum potassium levels in the most recent peritoneal dialysis guidelines [4] .
All parameters from haemodialysis patients audited in this report have used data collected mid-week before a 'short-gap' dialysis session in line with recommendations from the bone mineral guidelines as well as the haemodialysis guidelines [2, 3] .
Methods
The analyses presented in this chapter relate to biochemical variables in the prevalent dialysis cohort in the UK. The cohort studied were patients prevalent on dialysis treatment on 31 December 2016. Patients receiving dialysis for less than 90 days and those who had changed modality or renal centre in the last 90 days were excluded. HD and PD cohorts were analysed separately. A full definition of the cohort including inclusion and exclusion criteria is available in appendix B (www.renalreg. org/publications-reports/).
The biochemical variables analysed in this chapter were serum phosphate, calcium (adjusted for albumin), parathyroid hormone, bicarbonate and potassium. The method of data collection and validation by the UKRR has been previously described [7] . In brief, for each quarter of 2016 the UKRR extracted biochemical data electronically from clinical information systems in renal centres in England, Wales and Northern Ireland (E,W & NI). Cambridge renal centre (Addenbrooke's) was unable to submit 2016 data at patient level prior to the UKRR closing the database and only provided summary numbers of patients starting RRT by treatment modality. This centre is therefore excluded from most analyses in this chapter. Scottish centres have only been included in analyses relating to adjusted calcium and phosphate control, with data for their prevalent dialysis cohort being supplied directly by the Scottish Renal Registry. The UKRR does not currently collect data regarding different assay methods mainly because a single dialysis centre may process samples in several different laboratories. The audit measure used for serum phosphate was ,1.7 mmol/L in both the HD and PD cohorts [2] . However, for the audit measure of composite control of bone parameters it is recommended that all parameters are within the target range and this includes phosphate within the range of 1.1-1.7 mmol/L, so two different phosphate measures are in use in this chapter. For centres providing adjusted calcium values, these data were analysed directly as it is these values on which clinical decisions within centres are based. For centres providing unadjusted calcium values, the formula provided by each centre (or, if this is not available, a formula in widespread use) was used to calculate adjusted calcium [8] . The audit measure for adjusted calcium depends on the local reference range [2] . For the purposes of these analyses, the UKRR has used the RA guideline standard of adjusted calcium between 2.2-2.5 mmol/L as the audit measure [2] . There are also a variety of methods and reference ranges in use to measure PTH. To enable some form of comparative audit the UKRR has used two to nine times the median upper limit of the reference range (8 pmol/L) as the audit measure in line with the RA clinical practice guidelines and KDIGO 2017 guidance, which is unchanged from the previous KDIGO 2009 guidance [2, 6] . This equates to a PTH range of 16-72 pmol/L. The audit measure used for serum bicarbonate in the HD cohort was 18-24 mmol/L and in the PD cohort was 22-30 mmol/L as per the most recent guidelines [3, 4] . The audit measure for pre-dialysis serum potassium in the HD cohort uses the latest RA guideline Table 8 .2. Summary of clinical guideline target ranges and conversion factors from SI units
Biochemical variable
Clinical guideline measure Conversion factor from SI units Phosphate which is 4.0-6.0 mmol/L [3] . A summary of the current RA audit measures for these variables and conversion factors to SI units are given in table 8.2 . Quarterly values were extracted from the database for the last two quarters for calcium, phosphate, bicarbonate and potassium and the last three quarters for PTH. Patients who did not have these data were excluded from the analyses. Data completeness was analysed at centre and country level. All patients were included in analyses but centres with less than 50% completeness were excluded from plots and tables showing centre level performance. Data were also excluded from plots and tables when there were fewer than ten patients with data, both at centre or country level. These data were analysed to calculate summary descriptive statistics (maximum, minimum, mean with the corresponding standard deviation, median and interquartile range). Where applicable, the percentage achieving the RA standard or other surrogate clinical performance measure was also calculated.
The simultaneous control of all three components of bone and mineral disorder (BMD) parameters were analysed in combination. The proportion of patients with control of none, one, two or three parameters are presented. For the purpose of these analyses an adjusted calcium between 2.2-2.5 mmol/L, a phosphate level being maintained between 1.1-1.7 mmol/L and a PTH level between two and nine times the upper limit of normal (i.e. 16-72 pmol/L), were evaluated in combination.
Centres reported several biochemical variables with different levels of accuracy, leading to problems in comparative evaluation. For example, in the case of serum bicarbonate, data can be submitted as integer values but some centres submit data to one decimal place. All data have been rounded in an attempt to make centres more comparable.
Centres were requested to send pre-dialysis potassium levels for HD patients. Outlying centres were contacted and it was identified that post-dialysis potassium data had inadvertently been submitted and these centres have been excluded from the analysis. However, post-dialysis samples may remain within the analysis for some centres. Future data extracts will aim to ensure that only pre-dialysis results be submitted.
The number preceding the centre name in each figure indicates the percentage of missing data for that centre for that variable. Funnel plot analyses were used to identify outlying centres [9] . The percentage within range for each standard was plotted against centre size along with the upper and lower 95% and 99.9% confidence limits. Centres can be identified on these plots by looking up the number of patients treated in each centre in the relevant table and finding this value on the x-axis. Longitudinal analyses were performed for some data to calculate overall changes in achievement of a performance measure annually from 2006 to 2016 and were recalculated for each previous year using the rounding procedure.
All data are presented unadjusted for case-mix. The data were analysed using SAS 9.3.
Results

Mineral and bone variables Phosphate
In 2016 the following RA clinical practice guideline regarding phosphate management was applicable:
Guideline 3.2 CKD-MBD: Serum phosphate in dialysis patients ' We suggest that serum phosphate in dialysis patients, measured before a "short-gap" dialysis session in haemodialysis patients, should be maintained between 1.1 and 1.7 mmol/L.' [2] Audit measure: Percentage of patients CKD5D with serum PO4 <1.7 mmol/L [2] Pyart/Casula/Nicholas/Dawnay Pyart/Casula/Nicholas/Dawnay Pyart/Casula/Nicholas/Dawnay Overall, data from 22,435 HD and 2,999 PD patients across the UK were included in the analyses of serum phosphate in 2016. The overall data completeness for serum phosphate across the UK was 97.9% for both HD and PD patients, with some variation between centres (tables 8.3, 8.5). HD centre returns were all .90%, except Cambridge and Sunderland at 0%, and Colchester and Inverness with completeness between 80-85%. For PD patients, Cambridge also returned no data and only two other centres (Chelmsford and Inverness) returned less than 90% data, compared with five centres in the previous audit.
Haemodialysis
The individual centre means and standard deviations are shown in tables 8.3 and 8.5 for HD and PD patients respectively.
For those receiving HD, 59.9% of patients achieved a phosphate level below 1.7 mmol/L, the audit measure specified by the RA, and for those on PD this was In addition, a number of centres had achieved the serum phosphate control standard in a lower than expected proportion of patients (being below the lower 99.9% confidence interval): Birmingham Heartlands, Dundee, Edinburgh, Glasgow, Inverness, Kent and Preston (figure 8.2). Funnel plots for PD patients indicated that the control of phosphate levels were similar in all centres. Only two significant outliers were identified, Birmingham Heartlands and Derby, achieving the serum phosphate control standard respectively in a lower and in a higher than expected proportion of PD patients (figure 8.4).
Longitudinal analysis demonstrates that the proportion of HD and PD patients with hyperphosphataemia had seen modest improvement over the last decade however this proportion has increased in both modalities this year (figure 8.5). Data showing the performance of centres in attaining phosphate control within the guideline target range (1.1-1.7 mmol/L) can be found in appendix 1 of this chapter (rather than the audit measure of ,1.7 mmol/L presented here).
Simultaneous control of adjusted calcium, phosphate and PTH in preventing severe hyperparathyroidism In 2016 the following RA audit measure for combined biochemical control applied:
'Percentage of patients with all bone parameters within target range (Calcium/Phosphate/PTH)' [2] The RA guideline does not explicitly outline the target ranges to be used in the audit measure itself therefore the authors have interpreted this to include the target ranges suggested for each biochemical measure in the guideline. Therefore the combined audit measure comprised the following: phosphate 1.1-1.7 mmol/L, adjusted calcium 2.2-2.5 mmol/L and PTH 16-72 pmol/L. Please note this phosphate measure is discrepant with the preceding audit measure for phosphate alone (of ,1.7 mmol/L). This section presents only the audit measure of composite control, however data regarding attainment of each of the three components individually can be found in appendix 1.
There were combined biochemical results to assess mineral bone disease available from 57 HD and 55 PD centres, including 17,684 HD and 2,366 PD patients, from England, Wales and Northern Ireland in 2016. Table 8 .7 demonstrates the percentage of patients achieving results within the target range for none, one, two or all three bone mineral parameters, by centre for patients receiving HD and figure 8.6 shows the variation between centres in the proportion achieving control of all three parameters. Table 8 .8 and figure 8.7 show the same data for patients receiving PD.
Overall, 5.0% of HD and 3.3% of PD patients across England, Wales and Northern Ireland had none of the three bone mineral parameters controlled within the target ranges described above. Control of one parameter was reported in 24.8% of HD and 20.5% of PD patients; showed a large dispersal of attainment, 21 centres being above the 99.9% limit and 13 below the 99.9% limit. In contrast, the funnel plot for PD patients (figure 8.13) showed few outliers. Sample processing, case-mix, differences in dialysis, residual renal function and oral Pyart/Casula/Nicholas/Dawnay 
Centres missing from the table were excluded from analysis due to low patient numbers or poor data completeness
Peritoneal dialysis figure 8 .14. Achievement of bicarbonate audit measures has not changed significantly over the past decade for either modality. There has been a consistent difference between the modalities in the percentage with raised bicarbonate measures.
Potassium
In 2016 the following RA clinical practice guideline regarding potassium management in haemodialysis was applicable:
Haemodialysis Guideline 6.4 -HD: Pre-dialysis serum potassium concentrations 'We suggest that pre-dialysis serum potassium should be between 4.0 and 6.0 mmol/L in HD patients.' [3] The PD guideline contains no recommendation with regard to serum potassium.
A total of 10,568 HD patients' data were available for serum potassium analysis from 27 centres in England, all five centres in Northern Ireland but no centres in Wales in 2016. In total, data were 50.0% complete for HD patients (table 8.13). However, when considering only centres that submitted at least some data for serum potassium, centre completeness was 98% or higher apart from Stoke. The proportion of HD patients with serum potassium within the audit measure range was 84.1% in 2016 (95% CI 83.4-84.8%) (table 8.14); the mean serum potassium in HD patients was 4.9 mmol/L (table 8.13).
Some inter-centre variation was observed in attainment of the audit standard ( confidence interval limits. The serum potassium measurement will be particularly sensitive to differences in the timing and technique of sample processing by centre.
Discussion
Observational data continues to accumulate linking disordered calcium, phosphate and PTH levels with higher mortality in dialysis patients [10] [11] [12] [13] [14] [15] [16] . Despite this, trial data on specific target values or the best treatment approaches are lacking as reflected in recently published international guidelines [6] . The guidelines re-enforce the importance in identifying trends in parameters rather than reacting to isolated measurements and to appreciate the complex interdependency of parameters.
This chapter presents the results of mineral bone disease management for patients established on regular dialysis in the UK. Over the last decade there have been modest improvements in the attainment of target measures. In the latest analysis, a stable proportion of patients with all bone parameters within target range masks higher levels of hyperphosphataemia with improvement in attainment of target PTH. Increased hyperphosphataemia was seen across the majority of centres although there continued to be significant inter and intra centre variation in the attainment of target measures in part reflecting the challenge of managing the varied CKD-MBD phenotypes [6, 13] . As previously described, there were problems related to variations in calcium and PTH measurements between centres [17] . Comorbidity, dialysis dose and dialysate concentrations, as well as the use of phosphate binders, calcium mimetics and vitamin D analogues are also likely to be significant confounding variables at the patient level. The hope is that the expanded dataset will allow adjustment for these covariates in the near future.
Serum bicarbonate levels have not changed significantly compared with recent years, but there remained marked variation between centres in HD patients. The UKRR has previously conducted a limited survey [18] into the possible underlying causes of serum bicarbonate variation. The study examined measures of sample processing and of dialysis treatment. It did not adjust for case-mix and was unable to detect any significant differences between centres. Studies have identified an increased risk of death stratified by a reduced pre-dialysis serum bicarbonate level (,17 mmol/L) or with raised levels (.27 mmol/L) [19] [20] [21] , as well as with raised dialysate bicarbonate concentrates [11] . Future analysis of management of acidosis will have to re-explore the factors associated with an increased trend in developing alkalosis in HD patients.
Sufficient data were received from renal centres for the first time to analyse pre-dialysis potassium levels. Observational data has shown that pre-dialysis potassium levels both above 6.0 mmol/L and below 4.0 mmol/L have been associated with higher mortality thus forming the basis for the current guideline target range [3, [22] [23] . More recent analysis of the DOPPS data has shown, that after adjustment for patient factors including nutritional indicators, only higher potassium levels remained associated with higher mortality. Of the samples collected, 84.1% were within the target range which is slightly higher than the international data (81%) which included UK data [24] . Serum potassium levels are likely to be particularly sensitive to differences in the timing and processing of samples as well as differences in case-mix. Inter and intra centre variability therefore needs to be interpreted with caution. The current analysis used data collected before a 'short-gap' dialysis session in line with guidelines but in future it is planned to also analyse potassium collected before a 'long-gap' session if data completeness permits. This appendix includes analyses of the individual mineral bone measures that are included in the composite audit measure, namely adjusted calcium, phosphate and PTH within the recommended target ranges.
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Adjusted calcium
In 2016, the following RA clinical practice guideline regarding calcium management was applicable:
Guideline 2.2 CKD-MBD: Serum calcium in dialysis patients (stage 5D) ' We suggest that serum calcium, adjusted for albumin concentration, should be maintained within the normal reference range for the laboratory used, measured before a "short-gap" dialysis session in haemodialysis patients. Ideally, adjusted serum calcium should be maintained between 2.2 and 2.5 mmol/L, with avoidance of hypercalcaemic episodes (2D)' [2] In 2016, data from 22,552 HD and 3,006 PD patients across the UK were available for serum adjusted calcium Pyart/Casula/Nicholas/Dawnay Pyart/Casula/Nicholas/Dawnay 
Haemodialysis
Hence these data are shown after adjustment using a generic formula, and specific formulae provided some years ago by the laboratories serving Colchester, London West and Preston, have been applied.
Those formulae may not be applicable to the calcium and albumin methods used locally in 2016 and may have over-or under-estimated the adjusted calcium. These centres are served by laboratories that report adjusted calcium results and therefore it is hoped that adjusted calcium values be reported to the UKRR in future.
Of Pyart/Casula/Nicholas/Dawnay For those receiving HD, 55.2% of patients achieved a phosphate level between 1.1-1.7 mmol/L, the guideline specified by the RA (as opposed to the audit measure), and for those on PD this was 60.3% (tables 8.19, 8.20) .
There was inter-centre variation in the proportion of patients within the phosphate target range specified by the clinical guideline (figures 8.22-8.25, tables 8.19, 8.20) .
Funnel plots for HD patients with phosphate within the target range (1.1-1.7 mmol/L), show two centres (Birmingham Queen Elizabeth, Nottingham) attaining this standard in a significantly high proportion of patients (being above the 99.9% upper confidence interval following correction for centre size). In addition, only one centre (Birmingham Heartlands) had achieved the serum phosphate control standard in a lower than expected proportion of patients (being below the lower 99.9% confidence interval), (figure 8.23). Differences in outlier status can be seen when this guideline target measure is applied compared to the audit measure of phosphate ,1.7 mmol/L, namely fewer centres were found to be outliers.
The funnel plot for PD patients indicated that the control of phosphate levels was similar in all centres. No significant outliers were identified ( figure 8.25 ).
Longitudinal analysis had demonstrated stable performance against the clinical guideline recommendation Pyart/Casula/Nicholas/Dawnay In 2016, the proportion of HD patients with a PTH above the upper limit of the range (.72 pmol/L) was 17.9% and the proportion below the lower limit of the range (,16 pmol/L) was 23.8%.
The proportion of PD patients with PTH above the upper limit (.72 pmol/L) of the range was 13.4% and the proportion below the lower limit of the range (,16 pmol/L) was 20.9% (tables 8.22, 8.24) .
There was significant variation by centre following unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measures. The funnel plot (figure 8.28) for HD patients showed above average achievement of the target range in London Guys, Stevenage, Stoke and West NI and below average achievement for Exeter, Leicester, Liverpool Aintree, London West, Wolverhampton, Wrexham and York. For PD patients (figure 8.30) London Guys was above average achievement of the target range and there were no outliers below the 99.9% confidence interval for the target.
Longitudinal analysis of PTH control measures at the level of the three countries noted sustained reduction in the proportion of patients with low PTH levels (,16 pmol/L) in HD and PD patients. Similarly, there has been a corresponding increase in the fraction of HD and PD patients with PTH levels being maintained within the 16- 
